Does oxidative status affect serum sclerostin levels in patients with type 2 diabetes mellitus?

Basit Öğe Kaydı
dc.authorid0000-0002-0773-2752en_US
dc.authorid0000-0003-1415-0563en_US
dc.authorid0000-0002-5323-2257en_US
dc.contributor.authorSabancılar, İlhan
dc.contributor.authorUnsal, Velid
dc.contributor.authorDemir, Fidel
dc.contributor.authorToprak, Gülten
dc.contributor.authorPekkolay, Zafer
dc.date.accessioned2023-10-24T12:16:22Z
dc.date.available2023-10-24T12:16:22Z
dc.date.issued2023en_US
dc.departmentDicle Üniversitesi, Sağlık Bilimleri Enstitüsü, Biyokimya Ana Bilim Dalıen_US
dc.description.abstractIntroduction: Sclerostin is a glycoprotein known as a negative regulator of bone formation, predominantly expressed by mature osteocytes. There is no causative evidence information on the role of sclerostin in the pathogenesis of type 2 diabetes mellitus (T2DM) in humans. Aim: This study aimed to investigate the relationship between serum sclerostin levels and oxidative status and biochemical parameters in T2DM patients and healthy people. Materials and methods: This cross-sectional study, conducted in a clinical trial center, included 45 subjects with T2DM and 45 subjects as controls. Results: Serum sclerostin, total oxidative status (TOS), albumin, and ferritin levels were significantly higher in T2DM patients than in the control group (p<0.05). Total antioxidant status (TAS) was significantly higher in the control group (p<0.05). There was a weak positive correlation between sclerostin and TOS (r=0.23, p=0.03) and a weak negative correlation between sclerostin and TAS (r=−0.28, p=0.03). Conclusions: We have demonstrated that serum sclerostin levels increase in patients with T2DM and that the increased sclerostin levels are associated with oxidative stress.en_US
dc.identifier.citationSabancılar, İ., Unsal, V., Demir, F., Toprak, G. ve Pekkolay, Z. (2023). Does oxidative status affect serum sclerostin levels in patients with type 2 diabetes mellitus?. Folia Medica, 65(1), 46-52.en_US
dc.identifier.doi10.3897/folmed.65.e72953
dc.identifier.endpage52en_US
dc.identifier.issn0204-8043
dc.identifier.issue1en_US
dc.identifier.pmid36855973
dc.identifier.scopus2-s2.0-85149153498
dc.identifier.scopusqualityQ3
dc.identifier.startpage46en_US
dc.identifier.urihttps://foliamedica.bg/article/72953/
dc.identifier.urihttps://hdl.handle.net/11468/12917
dc.identifier.volume65en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorSabancılar, İlhan
dc.institutionauthorPekkolay, Zafer
dc.language.isoenen_US
dc.publisherMedical University of Plovdiven_US
dc.relation.ispartofFolia Medica
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSclerostinen_US
dc.subjectTASen_US
dc.subjectTOSen_US
dc.subjectType 2 diabetes mellitusen_US
dc.titleDoes oxidative status affect serum sclerostin levels in patients with type 2 diabetes mellitus?en_US
dc.titleDoes oxidative status affect serum sclerostin levels in patients with type 2 diabetes mellitus?
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Does Oxidative Status Affect Serum Sclerostin Levels in Patients with.pdf
Boyut:
564.7 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Sağlık Bilimleri Enstitüsü Makaleler
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu